Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II trial of Octreotate-Lu-177-DOTA-Tyr-3 in patients with various inoperable, somatostatin receptor positive NETs including bronchial carcinoid tumors

Next Previous
Trial Profile

A phase I/II trial of Octreotate-Lu-177-DOTA-Tyr-3 in patients with various inoperable, somatostatin receptor positive NETs including bronchial carcinoid tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
  • Indications Carcinoid tumour; Gastric cancer; Neuroendocrine tumours; Pancreatic cancer; Paraganglioma; Phaeochromocytoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 07 Feb 2019 According to an Advanced Accelerator Applications media release, based on results of this trial and phase III pivotal trial (NETTER-1), the Health Canada has approved Lutathera (lutetium (177Lu) oxodotreotide) for the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor-positive, gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults with progressive disease.
    • 01 Feb 2018 According to an Advanced Accelerator Applications media release, Advanced Accelerator Applications is acquired by Novartis
    • 26 Jan 2018 According to a Food and drug administration media release, based on results from this and NETTER-1 trials the U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top